Information on whether Atrasentan has been officially launched in China

The launch progress of atrasentan (atrasentan) in China has attracted much attention, especially among patients with primary immunoglobulin A nephropathy. Because of its novel mechanism of action and clear targeting, it is regarded as a new generation treatment option to improve proteinuria. According to the data, atrasentan has been officially approved in China, which means that its drug registration and marketing authorization procedures have been completed, and the policy conditions for entering the domestic market have been met. However, due to the short formal approval time and the fact that production, logistics, hospital network and channel construction are still in progress, the drug is still not available in most areas.

After many new drugs are approved in China, they will go through a transitional stage from "obtaining certificates" to "actually available for purchase." Atrasentan is at such a stage. Drugs need to complete batch release, commercial circulation, hospital pharmacy catalog storage, local network listing, doctor training and other steps. Therefore, it is normal that they cannot be purchased directly in hospitals or retail pharmacies in the short term. This process typically takes anywhere from a few months to a year, depending on how quickly companies supply it and whether the hospital makes it available for in-hospital use.

Although currently difficult to purchase, the domestic launch of atrasentan represents a major advance in the treatment of IgA nephropathy. In the past, patients usually relied on conventional proteinuria-lowering drugs or renin-angiotensin system blockers. As a new drug in the endothelin pathway, atrasentan provides a new treatment option for patients with persistently high proteinuria or who are at risk of progression. This mechanism innovation is believed to be expected to change the rate of disease progression and delay more patients from entering the stage of renal function deterioration.

Many hospitals are advancing processes such as drug introduction and Pharmacy Management Committee evaluation, and their in-hospital accessibility is expected to gradually improve. For patients in need of medicines, they can regularly consult the nephrology department or pharmacy of their hospital to obtain the latest shelf information.

Reference materials: https://www.vanrafia.com/